CAMBRIDGE, UK – 3 June 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events:
(1) American Society of Clinical Oncology (ASCO) Annual Meeting, 3–7 June 2016, McCormick Place, Chicago, Illinois, USA
Michael Koslowski, Chief Medical Officer, and Anker Lundemose, Chief Executive Officer, to attend conference
ASCO is one of the key global conferences in the Oncology space, bringing together 35,000 oncology professionals from around the world. The event has both educational and scientific sessions to address new therapies, treatment modalities, research and ongoing controversies in the field. Over 3,000 abstracts are submitted internationally from over 80 countries.
(2) Ubiquitin & Autophagy Conference, 4–7 July 2016, Goethe University Hospital, Frankfurt, Germany
The inaugural conference brings together leading experts in the field of quality control in cells, with a focus on ubiquitin and autophagy and will feature over 40 renowned speakers at the event.
(3) European Association for Cancer Research Conference (EACR), 9–12 July 2016, Manchester Central Convention Complex, Manchester, UK
The EACR is one of Europe’s largest dedicated conference on basic and translational research. This year’s theme is: ‘From Basic Research to Precision Medicine’ and will feature world class speakers from around the world covering the most innovative research topics in the fields of diagnostic tools and cancer treatment.
For further events, please visit the MISSION Therapeutics website.
For more information:
MISSION Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel +44 1223 497199
Mary Clark, Eva Haas, Hollie Vile
Tel: +44 (0) 20 7862 6390
NOTES TO EDITORS:
About MISSION Therapeutics
MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.
DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.
MISSION’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of MISSION and is the Chief Scientific Officer of the Company.
MISSION Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. MISSION is based at the Babraham Research Campus, south of Cambridge.